PL3265571T3 - System wielowektorowy i jego zastosowania - Google Patents

System wielowektorowy i jego zastosowania

Info

Publication number
PL3265571T3
PL3265571T3 PL16710113.8T PL16710113T PL3265571T3 PL 3265571 T3 PL3265571 T3 PL 3265571T3 PL 16710113 T PL16710113 T PL 16710113T PL 3265571 T3 PL3265571 T3 PL 3265571T3
Authority
PL
Poland
Prior art keywords
vector system
multiple vector
vector
Prior art date
Application number
PL16710113.8T
Other languages
English (en)
Inventor
Pasqualina COLELLA
Alberto Auricchio
Ivana TRAPANI
Original Assignee
Fondazione Telethon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fondazione Telethon filed Critical Fondazione Telethon
Publication of PL3265571T3 publication Critical patent/PL3265571T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/40—Systems of functionally co-operating vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
    • C12N2840/445—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor for trans-splicing, e.g. polypyrimidine tract, branch point splicing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
PL16710113.8T 2015-03-03 2016-03-03 System wielowektorowy i jego zastosowania PL3265571T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562127463P 2015-03-03 2015-03-03
PCT/EP2016/054602 WO2016139321A1 (en) 2015-03-03 2016-03-03 Multiple vector system and uses thereof

Publications (1)

Publication Number Publication Date
PL3265571T3 true PL3265571T3 (pl) 2022-09-05

Family

ID=56849204

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16710113.8T PL3265571T3 (pl) 2015-03-03 2016-03-03 System wielowektorowy i jego zastosowania

Country Status (19)

Country Link
US (2) US20180327779A1 (pl)
EP (2) EP4089172A3 (pl)
JP (2) JP7182873B2 (pl)
KR (1) KR102240180B1 (pl)
CN (1) CN107466325A (pl)
AU (1) AU2016227668B2 (pl)
BR (1) BR112017018728A2 (pl)
CA (1) CA2979120A1 (pl)
CY (1) CY1125385T1 (pl)
DK (1) DK3265571T3 (pl)
ES (1) ES2919880T3 (pl)
HR (1) HRP20220776T1 (pl)
MX (2) MX2017011255A (pl)
PL (1) PL3265571T3 (pl)
PT (1) PT3265571T (pl)
RS (1) RS63416B1 (pl)
SI (1) SI3265571T1 (pl)
SM (1) SMT202200269T1 (pl)
WO (1) WO2016139321A1 (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2986635T3 (en) 2013-04-18 2019-01-28 Fond Telethon EFFECTIVE DELIVERY OF BIG GENES THROUGH DUAL-AAV VECTORS
DK3265571T3 (da) * 2015-03-03 2022-06-27 Fond Telethon Fler-vektorsystem og anvendelse heraf
EP3719134B1 (en) * 2015-03-11 2023-08-23 The United States of America, as represented by The Secretary, Department of Health and Human Services Rp2 vectors for treating x-linked retinitis pigmentosa
WO2017108931A1 (en) * 2015-12-22 2017-06-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Improved hybrid dual recombinant aav vector systems for gene therapy
CN110225975A (zh) 2016-08-23 2019-09-10 阿库斯股份有限公司 用于治疗人受试者中非年龄相关的听力损害的组合物和方法
KR102606810B1 (ko) 2017-05-05 2023-11-27 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 오토펄린을 발현시키기 위한 조성물 및 방법
MA51918A (fr) * 2018-02-22 2020-12-30 Akouos Inc Compositions et méthodes de traitement d'une hypoacousie non associée à l'âge chez un sujet humain
RU2020132890A (ru) * 2018-04-05 2022-05-06 Оксфорд Юниверсити Инновейшн Лимитед Композиции и способы лечения макулярной дистрофии
AU2019255708B2 (en) 2018-04-17 2026-02-12 Ascidian Therapeutics, Inc. Trans-splicing molecules
US11660353B2 (en) 2018-04-27 2023-05-30 Decibel Therapeutics, Inc. Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems
CN112703016B (zh) 2018-04-27 2024-11-22 分贝治疗公司 肌球蛋白15启动子及其用途
US20210371878A1 (en) * 2018-10-15 2021-12-02 Fondazione Telethon Intein proteins and uses thereof
CN112888426A (zh) 2018-10-25 2021-06-01 百特奥尔塔公司 Aav三质粒系统
US12188041B2 (en) 2018-11-01 2025-01-07 University Of Florida Research Foundation, Incorporated Codon optimized otoferlin AAV dual vector gene therapy
AU2020218547A1 (en) 2019-02-08 2021-08-26 Decibel Therapeutics, Inc. Myosin 15 promoters and uses thereof
WO2020163743A1 (en) 2019-02-08 2020-08-13 Decibel Therapeutics, Inc. Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems
US12377168B2 (en) 2019-04-19 2025-08-05 University Of Massachusetts Gene therapies for usher syndrome (USH1B)
US20220315948A1 (en) 2019-04-26 2022-10-06 President And Fellows Of Harvard College Aav vectors encoding mini-pcdh15 and uses thereof
TW202129002A (zh) * 2019-12-09 2021-08-01 英商Ｕｃｌ商業有限責任公司 用於myh7關聯之心肌病之基因療法組合物及治療
JP2023512824A (ja) * 2020-02-07 2023-03-29 ザ チルドレンズ メディカル センター コーポレーション 大型遺伝子ベクターならびにその送達および使用の方法
IL295747A (en) 2020-02-21 2022-10-01 Akouos Inc Preparations and methods for the treatment of hearing impairment that is not related to age in humans
EP3885440A1 (en) * 2020-03-26 2021-09-29 Splicebio, S.L. Split inteins and their uses
CN115666658A (zh) 2020-04-01 2023-01-31 佛罗里达州大学研究基金会 具有提高的治疗ush1b的安全性的双aav-myo7a载体
CN112501209B (zh) * 2020-12-07 2024-02-13 和元生物技术（上海）股份有限公司 外源基因可控表达的腺相关病毒包装方法
EP4334447A1 (en) * 2021-05-07 2024-03-13 UCL Business Ltd Abca4 genome editing
WO2024098035A2 (en) * 2022-11-04 2024-05-10 National Resilience, Inc. Methods and compositions for preparing recombinant adeno associated viruses and uses thereof
WO2024258925A1 (en) 2023-06-12 2024-12-19 Children's Hospital Medical Center Aav-cftr vectors and methods of using same
CN116925239B (zh) * 2023-07-17 2024-10-18 苏州星奥拓维生物技术有限公司 双载体系统表达Otof基因的组合物和方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827702A (en) 1994-10-31 1998-10-27 Genentech, Inc. Ocular gene therapy
GB9720465D0 (en) * 1997-09-25 1997-11-26 Oxford Biomedica Ltd Dual-virus vectors
US6106826A (en) 1997-12-17 2000-08-22 Wisconsin Alumni Research Foundation Replication competent, avirulent Herpes simplex virus as a vector for neural and ocular gene therapy
ATE269412T1 (de) 1998-04-24 2004-07-15 Univ Florida Rekombinanter adeno-assoziierter viraler vektor, der alpha-1 antitrypsin kodiert, zur gentherapie
AU2003209226A1 (en) 2002-01-11 2003-07-30 Michael Tennant Adiponectin gene therapy
AU2003239151A1 (en) * 2002-04-19 2003-11-03 Georgia Tech Research Corporation Compositions and methods for the acceleration of protein secretion dynamics
WO2006036465A2 (en) 2004-09-03 2006-04-06 University Of Florida Compositions and methods for treating cystic fibrosis
JP4948845B2 (ja) 2006-02-08 2012-06-06 財団法人 東京都医学総合研究所 神経変性疾患治療用物質のスクリーニング方法
EP1998792B1 (en) * 2006-03-01 2015-02-18 The University of Utah Research Foundation Methods and compositions related to cyclic peptide synthesis
WO2007127428A2 (en) 2006-04-28 2007-11-08 University Of Florida Research Foundation, Inc. Double-stranded/self-complementary vectors with a truncated cba promoter and methods of gene delivery
US8658777B2 (en) * 2007-05-09 2014-02-25 The University Of Tokyo Activated protease indicator
US8236557B2 (en) * 2008-05-28 2012-08-07 University Of Missouri-Columbia Hybrid-AAV vectors to deliver large gene expression cassette
WO2010059763A1 (en) * 2008-11-19 2010-05-27 Amyris Biotechnologies, Inc. Compositions and methods for the assembly of polynucleotides
BRPI1014253A2 (pt) 2009-07-02 2016-04-12 Merz Pharma Gmbh & Co Kgaa polinucleotídeo codificado um polipeptídeo de neurotoxina, vetor, célula hospedeira, anticorpo, uso de um polinucleotídeo, método para a fabricação de um polipeptídeo de neurotoxina e método para a fabricação de um medicamento
WO2013075008A1 (en) * 2011-11-16 2013-05-23 University Of Florida Research Foundation Inc. Aav dual vector systems for gene therapy
DK2986635T3 (en) * 2013-04-18 2019-01-28 Fond Telethon EFFECTIVE DELIVERY OF BIG GENES THROUGH DUAL-AAV VECTORS
DK3265571T3 (da) * 2015-03-03 2022-06-27 Fond Telethon Fler-vektorsystem og anvendelse heraf

Also Published As

Publication number Publication date
SMT202200269T1 (it) 2022-09-14
JP2022174192A (ja) 2022-11-22
EP4089172A3 (en) 2023-03-01
KR102240180B1 (ko) 2021-04-14
HRP20220776T1 (hr) 2022-09-16
JP2018512125A (ja) 2018-05-17
BR112017018728A2 (pt) 2018-04-17
KR20170140185A (ko) 2017-12-20
EP3265571B1 (en) 2022-04-13
EP3265571A1 (en) 2018-01-10
DK3265571T3 (da) 2022-06-27
MX2023004479A (es) 2023-05-04
WO2016139321A1 (en) 2016-09-09
AU2016227668B2 (en) 2019-06-27
CA2979120A1 (en) 2016-09-09
US20180327779A1 (en) 2018-11-15
RS63416B1 (sr) 2022-08-31
MX2017011255A (es) 2018-08-01
SI3265571T1 (sl) 2022-10-28
PT3265571T (pt) 2022-06-29
AU2016227668A1 (en) 2017-08-31
JP7182873B2 (ja) 2022-12-05
CN107466325A (zh) 2017-12-12
CY1125385T1 (el) 2025-05-09
US20220002749A1 (en) 2022-01-06
EP4089172A2 (en) 2022-11-16
ES2919880T3 (es) 2022-07-28

Similar Documents

Publication Publication Date Title
SI3265571T1 (sl) Več vektorski sistem in njegove uporabe
GB2562423B (en) Cybersecurity system
IL255577B (en) Binding materials - tigit and their uses
GB201720065D0 (en) Systems and methods
IL253433A0 (en) Binders - tnfrsf and their uses
GB2549809B (en) Vector
GB201506119D0 (en) Systems and methods
SG10202108902YA (en) Ergonomic iv systems and methods
GB201601096D0 (en) System and assembly
PL3177259T3 (pl) System łączenia pojemników
SG11201707765XA (en) Search and rescue system
PL3365302T3 (pl) Układ mocujący i jego zastosowanie
GB201614093D0 (en) Vector
SG11201709032QA (en) Contactor and contactor system
ZA201801052B (en) Combinations and uses thereof
ZA201705375B (en) Continuous bagging processes and systems
GB201508175D0 (en) Methods and systems
IL254241A0 (en) Etv2 and its uses
HUE073224T2 (hu) Összekötõ- és tartályrendszer
GB201713486D0 (en) Collision-warning system
GB201518887D0 (en) Bopard carrying system and means
GB201608163D0 (en) Vector
GB201617213D0 (en) Telescopic-lateral system
TWM533404U (en) Aquaponics system
GB201612966D0 (en) System